SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
X	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* de Vries Glen Michael (Last) (First) (Middle) C/O MEDIDATA SOLUTIONS, INC. 350 HUDSON STREET, 9TH FLOOR (Street) NEW YORK NY 10014 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Medidata Solutions, Inc. [ MDSO ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title below) Other (specify below) President
	3. Date of Earliest Transaction (Month/Day/Year) 10/28/2019
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/20/2019		G	V	109,195	D	$0(1)	735,006(2)	D
Common Stock	10/28/2019(3)		D		620,750(4)	D	$92.25(4)	114,256	D
Common Stock	10/28/2019(3)		D		114,256(5)	D	(5)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.67	10/28/2019		D			75,058(6)	(7)	05/18/2020	Common Stock	75,058	(6)	0	D
Stock Option (right to buy)	$11.5	10/28/2019		D			70,300(6)	(7)	05/31/2021	Common Stock	70,300	(6)	0	D
Stock Option (right to buy)	$13.98	10/28/2019		D			72,174(6)	(7)	05/16/2022	Common Stock	72,174	(6)	0	D
Restricted Stock Units (Performance-Related)	$0.0	10/28/2019		D			74,856(8)	(9)	(9)	Common Stock	74,856	(8)	0	D
Restricted Stock Units (Performance Related)	$0.0	10/28/2019		D			73,176(8)	(10)	(10)	Common Stock	73,176	(8)	0	D
Restricted Stock Units (Performance-Related)	$0.0	10/28/2019		D			75,461(8)	(11)	(11)	Common Stock	75,461	(8)	0	D

Explanation of Responses:

1. Bona fide gift by the Reporting Person for no consideration.

2. Included are 130 shares which were purchased pursuant to the terms of the Medidata Solutions, Inc. Employee Stock Purchase Plan on June 30, 2019.

3. On October 28, 2019, pursuant to the Agreement and Plan of Merger, dated as of June 11, 2019, by and among Dassault Systemes SE ("DS"), Dassault Systemes Americas Corp., a Delaware corporation ("Parent"), 3DS Acquisition 6 Corp., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"), and Medidata Solutions, Inc., a Delaware corporation (the "Issuer"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent and an indirect wholly-owned subsidiary of DS (the "Merger").

4. Disposed of pursuant to the Merger Agreement and by virtue of the Merger, in which each share of Medidata common stock, par value $0.01 per share ("Issuer Common Stock"), issued and outstanding immediately prior to the completion of the Merger (other than restricted share awards held by continuing employees) was converted into the right to receive $92.25 in cash and without interest (the "Merger Consideration").

5. Represents restricted shares of Issuer Common Stock ("RSAs") that were outstanding immediately prior to the Merger. Pursuant to the Merger Agreement and by virtue of the Merger, each Issuer RSA was assumed by DS and converted into a restricted stock unit with the same remaining term and vesting schedule and relating to a number of ordinary shares of DS, par value EUR 0.5 per share ("Ordinary Shares"), equal to the product of (i) the total number of shares of Issuer Common Stock subject to such RSA immediately prior to the effective time of the Merger, multiplied by (ii) 0.6086, which represents the quotient obtained by dividing the Merger Consideration by (ii) the volume weighted average sales prices per share of Ordinary Shares for the ten full consecutive trading days ending on and including the business day that is three business day immediately prior to the closing date (the "Equity Award Conversion Ratio"), with any fractional shares rounded to the nearest whole number of shares.

6. Pursuant to the Merger Agreement and by virtue of the Merger, each option to purchase Issuer Common Stock will be cancelled and converted into the right to receive an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the total number of shares of Issuer Common Stock then covered by such option multiplied by (2) the excess, if any, of $92.25 per share over the exercise price per share under such option.

7. These options are fully vested and exercisable.

8. Pursuant to the Merger Agreement, each Issuer PBRSU was assumed by DS and converted into restricted stock with the same terms and conditions as were applicable to such PBRSU immediately prior to the effective time (except for the performance-based vesting conditions applicable to such PBRSU which will not apply from and after the effective time), and relating to a number of Ordinary Shares equal to the product of (i) the number of shares of Issuer Common Stock subject to such PBRSU immediately prior to the effective time based on the attainment of the applicable performance metrics (x) for the total stockholder return PBRSUs, at the actual level of performance through the effective time, as determined in good faith and consistent with past practice by the Issuer's board of directors or a committee thereof, and (y) for each other PBRSU, at the target level of performance, multiplied by (ii) the Equity Award Conversion Ratio, with fractional shares rounded to the nearest whole number.

9. Award of PBRSUs granted under the 2009 LTIP on February 23, 2017. The number of PBRSUs represented a target amount. Each PBRSU represented a contingent right to receive 0-200% of that target number of shares of the issuer's common stock, (i) 50% based on the issuer's TSR as compared to the TSR of companies in the Russell 2000 Index for the three years ending December 31, 2019, and (ii) 50% based on the Company's GAAP Net Income attainment for the three years ending December 31, 2019. The shares would have vested immediately upon being earned.

10. Award of PBRSUs granted under the 2017 LTIP on February 20, 2018. The number of PBRSUs represented a target amount. Each PBRSU represented a contingent right to receive 0-200% of that target number of shares of the issuer's common stock, (i) 50% based on the issuer's TSR as compared to the TSR of companies in the Russell 2000 Index for the three years ending December 31, 2020, and (ii) 50% based on the Company's GAAP Net Income attainment for the three years ending December 31, 2020. The shares would have vested immediately upon being earned.

11. Award of PBRSUs granted under the 2017 LTIP on February 12, 2019. The number of PBRSUs represented a target amount. Each PBRSU represented a contingent right to receive 0-225% of that target number of shares of the issuer's common stock, (i) 50% based on the issuer's TSR as compared to the TSR of companies in the Russell 2000 Index for the three years ending December 31, 2021, and (ii) 50% based on the Company's revenue attainment for the three years ending December 31, 2021. The shares would have vested immediately upon being earned.

Remarks:

	/s/ Michael I. Otner, Attorney-in-Fact	10/28/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.